HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Modest Increase To 2015 FDA Funds Includes $903.4 Mil. For CFSAN

This article was originally published in The Rose Sheet

Executive Summary

An omnibus spending agreement gives FDA about a 1.3% increase from its fiscal 2014 appropriation. CFSAN’s allocation of $903.4 million represents a more than 2% increase over fiscal 2014 enacted funding, consistent with the President’s budget request and the Senate’s proposed funding, but roughly $10 million less than the original House figure.

You may also be interested in...



Ebola Treatments Could Be Orphan Candidates – But Vaccines, Probably Not

FDA expects few people would get the disease in the U.S., but many could receive a vaccine.

FDA Budget: Compounding Increase Paid With Construction Funding, Efficiencies

Some planned buildings on the White Oak campus for FY 2015 would not be funded and savings from program efficiencies would create the $25 million in new funding for compounding oversight, Hamburg tells House committee.

FDA Opioid Guidance Is Silent On Generics, Cautions That Addicts Can Erase Labeling

Draft guidance on abuse-deterrent opioids notes that labeling claims may be revised if abusers outwit the abuse-resistant technology; the agency’s evaluation of generic-related citizen petitions continues.

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

RS019345

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel